Open Heart

OCTOBER 31, 2024

Background Heart failure (HF) is a leading cause of morbidity and mortality worldwide. Results Baseline characteristics revealed significant differences between NUA and HUA groups, with the latter exhibiting a higher prevalence of males, chronic kidney disease (CKD) and elevated levels of various biomarkers. in the NUA group.

Heart Failure 52

Heart Failure Kidney Disease Blood Pressure Biomarkers 52

DAIC

SEPTEMBER 19, 2024

recently announced that Digitiva, a non-invasive digital health solution for heart failure management, has been listed with the U.S. a smartphone app designed for heart failure patients and built on the Welldoc, Inc. a smartphone app designed for heart failure patients and built on the Welldoc, Inc.

Heart Failure 105

Heart Failure Technology Biomarkers Innovation 105

Circulation: Heart Failure

MARCH 14, 2025

Circulation: Heart Failure, Ahead of Print. Cardiovascular biomarkers and multimodality imaging may identify initial amyloidogenic organ involvement. The most common form of hereditary transthyretin cardiac amyloidosis (hATTR-CA) in the United States and the United Kingdom is the p.V142I variant.

Genetic predisposition 71

Genetic predisposition Heart Failure Biomarkers Circulation 71

Medical Xpress - Cardiology

JANUARY 2, 2024

A two-step screening protocol that combines clinical risk assessment with biomarker testing can more effectively identify which patients with type 2 diabetes need medication to prevent heart failure, according to a study led by UT Southwestern Medical Center researchers.

Heart Failure 78

Heart Failure Diabetes Biomarkers Research 78

Cardiovascular Diabetology

MARCH 20, 2025

The triglyceride-glucose index serves as a dependable biomarker for gauging insulin resistance linked to cardiovascular disease. Our study was designed to investigate how the trajectory of the triglyceride-glu.

Heart Failure 86

Heart Failure Biomarkers Cardiovascular Disease Diabetes 86

Medical Xpress - Cardiology

OCTOBER 10, 2024

Mavacamten, a drug initially developed to treat hypertrophic cardiomyopathy, has shown signs of reducing heart stress in patients with heart failure with preserved ejection fraction.

Preserved Ejection Fraction 97

Preserved Ejection Fraction Biomarkers Heart Failure Cardiomyopathy 97

DAIC

MAY 6, 2024

Initially discovered and developed by Orion Corporation in Finland, intravenous levosimendan is approved in 60 countries outside the United States for use in hospitalized patients with acutely decompensated heart failure. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

Preserved Ejection Fraction 105

Preserved Ejection Fraction Heart Failure Pulmonary Hypertension 105

Heart BMJ

MAY 10, 2024

While progress has been made in the management of most aspects of cardiovascular disease, the incidence and prevalence of heart failure (HF) remains high. Biomarkers have dramatically impacted the way patients with HF are evaluated and managed. The most studied biomarkers in HF are natriuretic peptides (NPs).

Biomarkers 52

Biomarkers Heart Failure Physiology Article 52

Frontiers in Cardiovascular Medicine

MARCH 3, 2024

Introduction Heart failure with preserved ejection fraction (HFpEF) is a complex disease process influenced by metabolic disorders, systemic inflammation, myocardial fibrosis, and microvascular dysfunction. Only 1 biomarker significantly correlated with both ECV and MPR.

Preserved Ejection Fraction 64

Preserved Ejection Fraction Biomarkers Heart Failure 64

American College of Cardiology

OCTOBER 9, 2024

What is the value of specific biomarkers for heart failure (HF) risk stratification in patients with atrial fibrillation (AF)?

Biomarkers 61

Biomarkers Atrial Fibrillation Heart Failure Article 61

European Journal of Heart Failure

NOVEMBER 29, 2023

ABSTRACT Aims Heart failure outcomes remain poor despite advances in therapy. The European Society of Cardiology Heart Failure III Registry (ESC HF III Registry) aims to characterize HF clinical features and outcomes and to assess implementation of guideline-recommended therapy in Europe and other ESC affiliated countries.

Heart Failure 75

Heart Failure Preserved Ejection Fraction Quality of Life Biomarkers 75

Open Heart

JANUARY 31, 2025

Life-threatening complications of infective endocarditis (IE,) are heart failure, uncontrolled infection and embolic events (EE), which pose significant morbidity and mortality risks.

Embolism 52

Embolism Biomarkers Heart Failure Risk Factors 52

Nature Reviews - Cardiology

MARCH 17, 2024

Nature Reviews Cardiology, Published online: 18 March 2024; doi:10.1038/s41569-024-01001-5 Non-coding RNAs are implicated in the pathophysiology of ischaemic heart disease and heart failure.

Biomarkers 67

Biomarkers Heart Disease Heart Failure 67

Frontiers in Cardiovascular Medicine

JULY 17, 2024

The triglyceride–glucose (TyG) index, proven to be a crucial insulin resistance biomarker (better than the Homeostasis Model Assessment for Insulin Resistance), is simple and non-invasive.

Heart Failure 64

Heart Failure Atherosclerosis Biomarkers Obesity 64

Journal of Cardiothoracic Surgery

JANUARY 9, 2025

MicroRNAs (miRNAs) are closely related to cardiovascular diseases, including chronic heart failure (CHF). Endothelial dysfunction can lead to heart failure. The purpose of this study was to evaluate the clinic.

Heart Failure 52

Heart Failure Biomarkers Cardiovascular Disease Research 52

American College of Cardiology

OCTOBER 16, 2024

He then explores an analysis from COMBINE-AF on heart failure (HF) risk assessment using biomarkers in patients with atrial fibrillation. In this week’s View, Dr. Eagle looks at an individual patient data meta-analysis of semaglutide and blood pressure (BP).

Biomarkers 57

Biomarkers Blood Pressure Atrial Fibrillation Stents 57

Frontiers in Cardiovascular Medicine

JANUARY 28, 2024

Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) have emerged as major age-related epidemics within cardiology. Indeed, these two conditions are commonly found in the same individual, so much so that AF has been used in proposed diagnostic criteria for HFpEF.

Preserved Ejection Fraction 59

Preserved Ejection Fraction Heart Failure Atrial Fibrillation Electrophysiology 59

Journal of Cardiothoracic Surgery

APRIL 22, 2024

It is essential to find reliable biomarkers for early diagnosis and prognosis of acute heart failure (AHF) for its mitigation. Currently, increasing attention is paid to the role of microRNAs (miRNAs/miRs) as.

Heart Failure 52

Heart Failure Biomarkers Research 52

Cardiovascular Diabetology

APRIL 28, 2024

Glycemic control, as measured by glycosylated hemoglobin (HbA1c), is an important biomarker to evaluate diabetes severity and is believed to be associated with heart failure development. Type 2 diabetes mellit.

Heart Failure 52

Heart Failure Diabetes Biomarkers Outcomes 52

Circulation: Heart Failure

OCTOBER 18, 2024

Circulation: Heart Failure, Ahead of Print.

Heart Failure 40

Heart Failure Biomarkers Circulation 40

Frontiers in Cardiovascular Medicine

JANUARY 7, 2024

Heart failure with preserved ejection fraction (HFpEF) is the largest unmet clinical need in cardiovascular medicine. Finally, we discuss the potential of ncRNAs as biomarkers and potential novel therapeutic targets for future HFpEF treatment.

Preserved Ejection Fraction 59

Preserved Ejection Fraction Heart Failure Biomarkers Cardiovascular Disease 59

Circulation: Heart Failure

JANUARY 5, 2024

Circulation: Heart Failure, Ahead of Print. BACKGROUND:Metabolomics has become a valuable tool for identifying potential new biomarkers and metabolic profiles. It has the potential to improve the diagnosis and prognosis of different phenotypes of heart failure. Additionally, symmetrical dimethylarginine (mean, 1.97±0.61

Heart Failure 40

Heart Failure Biomarkers Cardiomyopathy Circulation 40

Circulation

JULY 28, 2024

Circulation, Volume 150, Issue 5 , Page 390-392, July 30, 2024.

Heart Failure 49

Heart Failure Biomarkers Circulation 49

Circulation

APRIL 16, 2025

The growing morbidity, mortality, and health care costs related to heart failure (HF) underscore the urgent need to prioritize its primary prevention. Whereas a risk-based approach for HF prevention remains in its infancy, several key opportunities exist to actualize this paradigm in clinical practice.

Heart Failure 45

Heart Failure Cardiovascular Disease Biomarkers Circulation 45

European Journal of Heart Failure

MARCH 30, 2025

Metabolic dysfunction and incident heart failure. Aims The extent to which metabolic syndrome (MetS) severity influences subclinical myocardial remodelling, heart failure (HF) incidence and subtypes, remains unclear. CI, confidence interval; MetS, metabolic syndrome.

Heart Failure 40

Heart Failure Preserved Ejection Fraction Biomarkers BMI 40

DAIC

JULY 10, 2024

The promising results of the study confirm the potential of our therapy to provide an effective one-off solution to prevent heart failure progression in AMI patients,” said Matthieu de Kalbermatten , CEO, CellProthera. “We

Myocardial Infarction 105

Myocardial Infarction Heart Failure Heart Attack Heart attacks 105

Frontiers in Cardiovascular Medicine

JANUARY 7, 2024

Objectives In dyspneic patients with atrial fibrillation (AF) or obesity, the diagnostic performance of NT-proBNP for acute heart failure is reduced.

Heart Failure 59

Heart Failure Circulation Obesity Atrial Fibrillation 59

DAIC

APRIL 9, 2024

Decline in exercise ability is a hallmark of progression to overt heart failure. These results also speak to the importance of continuing to focus on earlier recognition of heart failure risk in patients with diabetes and on initiating treatment before the condition has progressed to overt heart failure.”

Heart Failure 52

Heart Failure Diabetes Cardiomyopathy Exercise 52

Circulation: Heart Failure

SEPTEMBER 12, 2023

Circulation: Heart Failure, Volume 16, Issue 11 , Page e010618, November 1, 2023. BACKGROUND:Obesity and adiposity are associated with an increased risk of heart failure with preserved ejection fraction (HFpEF); yet, specific underlying mechanisms remain unclear. mL/kg per min lower peak VO2(β, −2.35±0.19;P<0.001).

Biomarkers 40

Biomarkers Obesity Exercise Preserved Ejection Fraction 40

European Journal of Heart Failure

SEPTEMBER 26, 2023

Abstract Diagnosing heart failure is often difficult due to the non-specific nature of symptoms, which can be caused by a range of medical conditions. Natriuretic peptides (NPs) have been recognized as important biomarkers for diagnosing heart failure.

Heart Failure 40

Heart Failure Coronary Artery Disease Outpatient Document 40

DAIC

APRIL 9, 2024

The PROACT study reported no impact on cardiotoxicity biomarkers or secondary endpoints related to heart function among patients who took high doses of enalapril, an ACE inhibitor, along with high doses of anthracyclines.

ACE Inhibitor 105

ACE Inhibitor Cancer Biomarkers Heart Failure 105

Circulation: Heart Failure

JANUARY 16, 2025

Circulation: Heart Failure, Ahead of Print. BACKGROUND:Right ventricular dysfunction (RVD) is common in patients with heart failure with reduced ejection fraction, and it is associated with poor prognosis.

Biomarkers 40

Biomarkers Heart Failure Heart Transplant Transplant 40

HeartRhythm

APRIL 30, 2024

Leukocyte telomere length (LTL) is a well-established biomarker linked to cardiovascular disease, with shorter LTL associated with increased severity of heart failure (HF) outcomes. It is also well known that atrial fibrillation (AF) and HF are closely related and often coexist.

Atrial Fibrillation 40

Atrial Fibrillation Heart Failure Biomarkers Cardiovascular Disease 40

Frontiers in Cardiovascular Medicine

OCTOBER 10, 2024

BackgroundWe conducted a large-scale epidemiological analysis to investigate the associations between systemic inflammation markers and heart failure (HF).

Heart Failure 52

Heart Failure Biomarkers 52

Journal of the American Heart Association

JANUARY 12, 2024

Journal of the American Heart Association, Ahead of Print. ABSTRACT: Albuminuria, an established biomarker of the progression of chronic kidney disease, is also recognized as a biomarker for the risk of cardiovascular disease. However, screening for albuminuria is still low.

Cardiovascular Disease 71

Cardiovascular Disease Risk Factors Coronary Artery Disease Kidney Disease 71

Circulation

JANUARY 22, 2025

In our study, NT-proBNP provided little value in those with AF and dyspnea because the presence of AF is by itself a robust biomarker of HFpEF. Circulation, Ahead of Print.

Preserved Ejection Fraction 55

Preserved Ejection Fraction Outpatient Heart Failure BMI 55

Cardiovascular Diabetology

MARCH 7, 2025

Coronary artery disease (CAD) and diabetes mellitus (DM) can induce changes in myocardial structure and function, thereby increasing the risk of heart failure (HF). We aimed to identify the alterations in echo.

Coronary Artery Disease 52

Coronary Artery Disease Diabetes Biomarkers Heart Failure 52